Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.
You may also be interested in...
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.